Results 11 to 20 of about 2,874 (159)
An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam [PDF]
Infectious Diseases and Therapy, 2020 Plain Language Summary Carbapenem-resistant gram-negative pathogens, specifically, Enterobacteriaceae, remain an urgent public health threat, and safe, effective treatment options are limited. The antibiotic agents meropenem and vaborbactam were selected
Eric Wenzler, Patrick J. Scoble
doaj +3 more sources
Biochemical Activity of Vaborbactam [PDF]
Antimicrobial Agents and Chemotherapy, 2020 The most common mechanism of resistance to β-lactams antibiotics in Gram-negative bacteria is production of β-lactamase enzymes capable of cleaving the β-lactam ring. Inhibition of β-lactamase activity with small-molecule drugs is a proven strategy to restore the potency of many β-lactam antibiotics.
Tsivkovski, Ruslan, Lomovskaya, Olga
openaire +2 more sources
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
Antibiotics, 2021 The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci +3 more
doaj +1 more source
Antibiotics, 2023 Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for the management of difficult-to-treat Gram-negative infections.
Rossella Barone +6 more
doaj +1 more source
Antibiotics, 2023 Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives.
Anna Duda-Madej +2 more
doaj +1 more source
Potency of Meropenem-Vaborbactam in Lung Surfactant [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several Klebsiella pneumoniae carbapenemase (KPC ...
Debora, Rubio-Aparicio +3 more
openaire +2 more sources
Antibiotics, 2022 The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco +7 more
doaj +1 more source
Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales [PDF]
Journal of Antimicrobial Chemotherapy, 2023 Abstract Background The treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE) are extremely scarce nowadays and the development of new antibiotics does not follow the exponential increase in the dissemination of carbapenem resistance determinants worldwide.
Patrice Nordmann +5 more
openaire +2 more sources
Antibiotics, 2023 Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin +6 more
doaj +1 more source
Profiling interactions of vaborbactam with metallo-β-lactamases [PDF]
Bioorganic & Medicinal Chemistry Letters, 2019 β-Lactams are the most successful antibacterials, yet their use is threatened by resistance, importantly as caused by β-lactamases. β-Lactamases fall into two mechanistic groups: the serine β-lactamases that utilise a covalent acyl-enzyme mechanism and the metallo β-lactamases that utilise a zinc-bound water nucleophile.
Langley, G +11 more
openaire +7 more sources